Asset profile
Hrain anti-BCMA CAR-T
Cell therapy
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 51 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Hrain Anti-BCMA CAR-T: this drug | Phase 2 | Cell therapy | CAR-T cell therapy | ||
| JY232 | Phase 1 | Cell therapy | CAR-T cell therapy | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Melphalan Flufenamide | Approved | Small molecule | DNA (alkylation), delivered via aminopeptidase-mediated intracellular activation |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(27 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
December 2026 (4)
What to watch
What to watch
What to watch
What to watch
2027 (16)
January 2027 (1)
What to watch
February 2027 (2)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (4)
What to watch
What to watch
What to watch
What to watch
October 2027 (2)
2028 (6)
February 2028 (1)
What to watch
March 2028 (3)
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
July 2028 (1)
What to watch
2035 (1)
December 2035 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.